# Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

> **NCT00266812** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 35 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Temozolomide and radiotherapy
- **PROCEDURE:** Whole brain radiotherapy

## Key facts

- **NCT ID:** NCT00266812
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03-08
- **Primary completion:** 2008-01-16
- **Final completion:** 2008-01-16
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Patient target could not be reached within the planned timeframe.
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266812, "Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00266812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*